FDA Grants Extra Patent Time for BEYFORTUS Baby Drug
Published Date: 6/16/2025
Notice
Summary
The FDA has officially set the review period for BEYFORTUS, a human biological product, so its patent can be extended. This means the company behind BEYFORTUS gets extra time to protect their invention and keep making money. Anyone interested in patent timing or drug development should take note of this important update.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA OKs Patent Extension Timing
The FDA has determined the regulatory review period for BEYFORTUS so the patent holder can seek an extension of the patent that claims this human biological product. This gives the company extra time to protect the invention and continue earning revenue from the product.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in